Brainstorm Cell Therapeutics Stock Forecast, Price & News

+0.51 (+14.49 %)
(As of 07/30/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume547,246 shs
Average Volume153,330 shs
Market Capitalization$146.37 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive BCLI News and Ratings via Email

Sign-up to receive the latest news and ratings for Brainstorm Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Brainstorm Cell Therapeutics logo

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and in Phase II for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other central nervous system disorders. The company has a partnership with Catalent for the manufacture of NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.14 out of 5 stars

Medical Sector

410th out of 2,220 stocks

Biological Products, Except Diagnostic Industry

58th out of 213 stocks

Analyst Opinion: 3.5Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Frequently Asked Questions

Is Brainstorm Cell Therapeutics a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Brainstorm Cell Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Brainstorm Cell Therapeutics stock.
View analyst ratings for Brainstorm Cell Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Brainstorm Cell Therapeutics?

Wall Street analysts have given Brainstorm Cell Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Brainstorm Cell Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics saw a decrease in short interest in June. As of June 30th, there was short interest totaling 1,400,000 shares, a decrease of 60.9% from the June 15th total of 3,580,000 shares. Based on an average daily volume of 409,300 shares, the days-to-cover ratio is presently 3.4 days. Currently, 4.7% of the company's stock are short sold.
View Brainstorm Cell Therapeutics' Short Interest

When is Brainstorm Cell Therapeutics' next earnings date?

Brainstorm Cell Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Brainstorm Cell Therapeutics

How were Brainstorm Cell Therapeutics' earnings last quarter?

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) announced its earnings results on Sunday, April, 25th. The biotechnology company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.07.
View Brainstorm Cell Therapeutics' earnings history

How has Brainstorm Cell Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Brainstorm Cell Therapeutics' stock was trading at $6.68 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BCLI shares have decreased by 39.7% and is now trading at $4.03.
View which stocks have been most impacted by COVID-19

What price target have analysts set for BCLI?

1 Wall Street analysts have issued 1 year price targets for Brainstorm Cell Therapeutics' shares. Their forecasts range from $12.00 to $12.00. On average, they expect Brainstorm Cell Therapeutics' share price to reach $12.00 in the next year. This suggests a possible upside of 197.8% from the stock's current price.
View analysts' price targets for Brainstorm Cell Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Brainstorm Cell Therapeutics' key executives?

Brainstorm Cell Therapeutics' management team includes the following people:
  • Mr. Chaim Lebovits, Chief Exec. Officer (Age 50, Pay $1.64M)
  • Dr. Irit Arbel Ph.D., DSc, Co-Founder & Independent Vice Chair of the Board (Age 61)
  • Dr. Ralph Z. Kern, Pres & Chief Medical Officer (Age 63, Pay $844.22k)
  • Mr. Uri Yablonka, Exec. VP, Chief Bus. Officer, Sec. & Director (Age 44)
  • Dr. Preetam Shah M.B.A., Ph.D., Exec. VP, CFO & Treasurer (Age 48)
  • Dr. David Setboun M.B.A., Pharm.D., Exec. VP & COO (Age 46)
  • Dr. Yael Gothelf, VP of Scientific & Regulatory Affairs
  • Dr. Daniel Offen, Chief Scientific Advisor
  • Dr. Stacy R. Lindborg Ph.D., Exec. VP & Head of Global Clinical Research (Age 50)
  • Mr. William K. White, Sr. VP & Head of Market Access and Pricing

Who are some of Brainstorm Cell Therapeutics' key competitors?

What other stocks do shareholders of Brainstorm Cell Therapeutics own?

What is Brainstorm Cell Therapeutics' stock symbol?

Brainstorm Cell Therapeutics trades on the NASDAQ under the ticker symbol "BCLI."

How do I buy shares of Brainstorm Cell Therapeutics?

Shares of BCLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Brainstorm Cell Therapeutics' stock price today?

One share of BCLI stock can currently be purchased for approximately $4.03.

How much money does Brainstorm Cell Therapeutics make?

Brainstorm Cell Therapeutics has a market capitalization of $146.37 million. The biotechnology company earns $-31,810,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis.

How many employees does Brainstorm Cell Therapeutics have?

Brainstorm Cell Therapeutics employs 39 workers across the globe.

What is Brainstorm Cell Therapeutics' official website?

The official website for Brainstorm Cell Therapeutics is

Where are Brainstorm Cell Therapeutics' headquarters?

Brainstorm Cell Therapeutics is headquartered at 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY, 10019.

How can I contact Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics' mailing address is 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY, 10019. The biotechnology company can be reached via phone at 201-488-0460 or via email at [email protected]

This page was last updated on 8/1/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.